Dentist Faces DEA Hammer in Drug Prescribing Showdown
Published Date: 10/30/2025
Notice
Summary
Dr. Lawrence Michael Willis from Colorado lost his DEA registration because he didn’t follow state rules about checking the Prescription Drug Monitoring Program. He didn’t ask for a hearing in time, so the government revoked his registration by default. This means he can’t legally handle controlled substances anymore, effective immediately, which could impact his dental practice and income.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Revoked; Colorado Renewals Denied
The DEA revoked Lawrence Michael Willis's Certificate of Registration No. AW1335822 and denied any pending applications to renew or modify that registration as well as any other pending application for additional registration in Colorado. The Agency found he failed to register for and query the Colorado Prescription Drug Monitoring Program and issued at least 195 opioid and benzodiazepine prescriptions without querying the PDMP between July 2018 and June 2023. The revocation and denials are effective December 1, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-19704, Committee and Quarterly Board Meetings
The National Assessment Governing Board is holding its committee and quarterly meetings in person and online on November 20-21, 2025. Anyone interested must register online five days before the meetings to join virtually. These meetings let the public learn about and comment on important education policies, with no new costs or major changes announced.
Next: 2025-19707, Dawn Evert, N.P.; Decision and Order
Dawn Evert, a nurse practitioner from Colorado, had her DEA registration suspended and then revoked because she prescribed dangerous drugs without proper medical reasons or monitoring. This decision protects public safety by stopping her from legally prescribing controlled substances. The revocation is final, even though her registration expired in August 2025, so she can’t prescribe these drugs anymore.